BlackRock, Inc. 13D and 13G filings for Neurocrine Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-23 11:52 am Purchase |
2023-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
13,647,679 13.900% |
1,020,276 (+8.08%) |
Filing |
| 2023-01-23 3:52 pm Purchase |
2022-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
12,627,403 13.100% |
1,150,858 (+10.03%) |
Filing |
| 2022-01-27 1:59 pm Unchanged |
2021-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
11,476,545 12.100% |
0 (Unchanged) |
Filing |
| 2022-01-25 6:45 pm Purchase |
2021-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
11,476,545 12.100% |
486,899 (+4.43%) |
Filing |
| 2021-04-09 6:00 pm Purchase |
2021-03-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
10,989,646 11.700% |
3,991,851 (+57.04%) |
Filing |
| 2021-01-29 5:23 pm Purchase |
2020-12-31 | 13G | Neurocrine Biosciences, Inc. NBIX |
BlackRock Inc. BLK |
6,997,795 7.500% |
406,243 (+6.16%) |
Filing |